Patent ID: 8741349

Claim:
An antiviral material comprising tungsten oxide composite microparticles having a mean primary particle diameter (D50) in a range of 2 to 100 nm, wherein the microparticles, which are undergone a test to evaluate a virus titer by inoculating on a specimen, to which the microparticles are adhered in a range of not less than 0.01 mg/cm 2 nor more than 40 mg/cm 2 , at least one virus selected from a pathogenic avian influenza virus H9N2, H5N1, and a swine influenza virus, and irradiating with visible light having a wavelength of 380 nm or more and illuminance of 6000 1× for 24 hours by using a white fluorescent lamp and an ultraviolet cutting filter, by a method based on Test method for antibacterial activity of photocatalytic products under photoirradiation and efficacy of JIS-R-1702 (2006), have an inactivation effect R of 1 or more expressed by following: R =log C −log A wherein C denotes a virus titer tissue culture infective dose (TCID50) obtained after irradiating an unprocessed specimen with the visible light for 24 hours, and A denotes a virus titer TCID50 obtained after irradiating the specimen having the microparticles with the visible light for 24 hours, wherein the tungsten oxide composite contains at least one element selected from transition metal elements except tungsten in a range of 0.01 to 50 mass %.